Although previous reports suggested that the NF-κB activation might contribute to the development of resistance to anti-cancer drugs such as cisplatin and 5-FU in OSCC [26,27], the molecular mechanism for NF-κB pathway activation in OSCC patients has largely yet to be determined. The gene discussed is NFKB1; the disease is cancer.